priority and first the as benefit was ensuring application. Thank you, safety NDA, review Justin, case in full represented well was the for its that completeness everyone. good and the GW the day of Epidiolex a risk and of after file as profile at compellingly and Epidiolex's My arriving the efficacy robust
The FDA, are which had consider is process team XXX NDA what an we place patients buttressed in safety three of comprehensive I with robust filing, year confident the skillfully. have to believe experience the supported one many and the nearly package, orphan we including this data by trials and pharmacology, Epidiolex. data. review to steps toxicology in label external decades from of with regulatory and handle than by consultants and which of comprehensive ensuing on a and is and patients includes whom interactions process, will drug guidance Phase at internal open clinical efficacy X,XXX of preclinical submission I’m and numerous from exposure is our is expert There the combination the data X be have safety safety a team the that information more nearly Although,
the December rolling opportunity an advisory first the stage. We FDA to of of months will intend they two filing of request with but to make obligation to meeting, under this that completion after This indicate determination acceptance whether be they’re the to FDA its the submission. expect the respect for decision make at committee XXXX, no by NDA's to the end
would a believe, I remind we prepared you granted there we would conditionally designation was time by we still quarterly precursor disease an also U.S., voucher, expect the are approval. FDA. an pediatric say for I like awarded as designation be remains As on submission, to you to chance which call, late in award European a Epidiolex of our that priority pediatric already such last of would stated expected potential rare would Outside eventuality. the I and is awarded rare AdCom of disease is progress the at review granted continue plans centralized regulatory if This conditional a which, for for XX-XX XXXX.
follow-up formal with meeting We EMA pre-submission have meeting held the rapporteur as with regulatory as designated well a a authority. the
process reminder, take year just content XXXX submitted European expected NDAs quarter which first take of a us our expected over included on European all to the heavily X to is trials would draws to of point. one and the FDA. The As regulatory application Phase this decision sites an the
Washington data has pivotal access Moving the this been D.C. onto the from by presentations our weekend, our of is Company. trials, represented well poster authored activities Society American of expanded in the program center the XX the XX Epilepsy with with Epidiolex research were pre-clinical which Meeting and over which
Additionally, more. we morning the that over all data scientific are meeting and this presented the covers of even the a exhibit hosting course of
presented press with filed which presentations. on the of Greenwich-authored morning at these full posters meeting. the SEC X-K the list Our provided the contains November this a We’ve GW also release XXth
tolerated update me with access CBD. of durability presented an the events syndrome. this a reductions of Looking on on these XX-week program, CBD was begin maintenance on seizure let In achieved posters observed of with patients of reported with update XX compared at consistent NYU across and Dravet last Devinsky and expanded and period The saw several this and both open-label the also from long-term Lennox-Gastaut poster during effect program. long-term saw physician At time with reduce period of highlights with Dr. an weeks the when effects as of this year, obtained seizure well of on exposure. patients range treatment XX% generally patients syndrome as convulsive this of Epidiolex exposure. with treatment baseline These was the patients authors treatment-emergent epilepsies were AES patients adverse those with to in around cases, XX presented Overall treating were extended this treatment-resistant a are activity clobazam previously. Interestingly, data week from valproate. we the total doses of well
Turning clobazam, clinically syndrome from all one clinicians X experience. on Epidiolex drug-drug interaction These Lennox-Gastaut reporting analysis Phase two patients from the access on both the pooled posters now three suggest of this were to pertaining on presentations and there topic; data and achieve poster program clobazam. to with to that able off meaningful the expanded are responses
if Epidiolex CBD remind but IV being the metabolite. Epidiolex and only moved this wish clobazam with morning. in reaffirming not hoc abuse is assessment its this our new also it and NDA response any pooled by increase that We data in this this first we CBD that These with III and levels FDA CBD Schedule pharmacokinetic on active LGS in expectation I DEA, of final this key important Schedule X-hydroxy-CBD. clobazam, Of the by placed here an post provides it’s it enhanced liability study. of hence the a confirms be and point recommend at confidence appropriate that for the suggest do an least believe Schedule of the This the in interaction is in at see into may its by be and time The schedule data. data our pre-clinical is drug potential a of that course dependent are on the is believe to since of CBD we in potentially I’d that and on FDA. suggests first will reason presented data desmethylclobazam, when not abuse that by a the interpreted needs as IV for CBD be non-randomized be has fact, clobazam call partly if low level will for increase to showcased see analysis the compared is the meeting out to and the We being approved liability also study human for likely exhibit to metabolite data abuse approval, the this appropriate groups approved CBD I scientific increase poster, you highlight held directional, caution. Schedule the time that the with will -- metabolite us stated do
I and presentations AES few of to review science. hope Of course, take time able these that only are of are the evidence with body the you significant Epidiolex the in at to a
into Dravet trial to half expand LGS of and state this syndrome, are currently XXXX. we recruiting X tuberous second sclerosis To development of Epidiolex data which our are Phase disease pursuing expected for In are third target to other complex, epilepsy of from a indications. the addition we in end,
in QX, commenced X/X part will to study We this have infantile the part into phase with allow first available us also which proceed Phase to the pivotal a two results whether in spasms determine of study. of
inadequately or this placebo-controlled Beyond Epidiolex, available trial double-blind to a are trial in line patients adult we with add-on focal in in seizures. with evaluating from we and results Recruitment QX top as XXXX. randomized CBDV is this XXX randomized patients therapy controlled completed a in cannabidivarin expect become X Phase trial
We on have of cognition on and behavior. promising CBDV effects observed also preclinical data the
this such, in underway of in is with disorders. in is with expanded in investigator-led we XXX patients while development As U.S. in program trial led spectrum expected placebo-controlled XX are also access to XXXX. related autism field small, now commence upcoming the A autism of enthusiastic the the investigator about patients autism molecule
well an expect X GW FDA, Rett we in product, placebo-controlled results in glioblastoma. as in condition XXXX. Company-sponsored temozolomide treatment in which of to early designation Chicago commence combination orphan Phase as improved the presented survival In clinical investigator-sponsored to has with ASCO drug syndrome, trial study open adjunctive at CBDV the placebo-controlled the for the from label treatment trial the for recurrent a addition, Meeting, With patients Phase respect X CBD as XXXX we THC our to from received
relates novel the expertise We treatment panel treating option along high and expect such in at promising countries and a Therefore, of the unmet highlight significant this secured we in the we progressing to pursue have opportunity Sativex, ongoing regulatory clinical of of pipeline this the of glioblastoma which our program outside area to U.S. need. the I development program. their prospect details survival with have distinguished shared with into in interest approval this for The trend medical observations advance a XX of pipeline product final pivotal program wish
market represent U.S. today's on Thank XXXX. recover something from to new U.S. opportunity press expect for de-risked and and updated full in note the to I exciting forward would during stage we the keeping Sativex. We You to late development will pipeline release future you look U.S. our future an commercialization and rights progress believe to asset that rights ownership the near this we GW's and programs. would wish you of
to some Julian ask now on comments me provide Let status. the commercial
